目的　探讨简化的抗凝指标检测法及低抗凝强度的华法令应用于心房颤动 (简称房颤 )的可行性。方法　 115例房颤患者随机分为低抗凝强度组 (INR 1 5～ 2 0 )和标准抗凝强度组 (INR 2 1～ 3 0 ) ,在服华法令后第4日采血检测INR ,以后每周 1次至每月检测 1次。结果　 95 7%病例第 4日检测的INR≤ 3 0 ,只有 1例INR达4 0伴皮肤出血 (占 0 9% ) ;平均随访 3.4年 ,低抗凝强度组栓塞年发生率 0 98% ,标准抗凝强度组未发生栓塞 ,但两组比较差异无显著意义 (P >0 0 5 ) ;出血年发生率分别为 0 4 9%和 3 74 % ,两组比较差异有显著意义 (P <0 0 5 )。结论　简化的抗凝指标检测法是可行的 ;对非瓣膜性房颤可考虑应用低抗凝强度的华法令 ,瓣膜性房颤仍需标准抗凝强度的华法令治疗。 Objective To investigate the feasibility of using simplified anticoagulation method and warfarin with low anticoagulant strength for atrial fibrillation. Methods One hundred and fifteen patients with atrial fibrillation were randomly divided into low anticoagulant group (INR 1 5 ~ 20) and standard anticoagulation group (INR 2 1 ~ 3 0). Blood samples were collected on the 4th day after warfarin treatment, Once a week to test once a month. Results Ninety-seven percent of the patients with INR of 30 days on the 4th day had only 1 case of INR with 40% bleeding (0 9%); mean follow-up was 3.4 years, and the incidence of embolization in the low anticoagulation group was 98% The standard anticoagulation strength group did not embolize, but there was no significant difference between the two groups (P> 0.05). The incidence of hemorrhage was respectively 0.49% and 3.74%, the difference between the two groups was significant (P < 0 0 5). Conclusions Simplified anticoagulation method is feasible. Warfarin with low anticoagulant strength can be considered for non-valvular atrial fibrillation. Valvular atrial fibrillation still needs standard anticoagulation with warfarin.